Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2022

    

2021

Revenue

​

​

​

​

​

​

Qbrexza®

​

$

26,715

​

$

17,056

Accutane®

​

​

18,373

​

​

10,053

Amzeeq®

​

​

7,242

​

​

—

Targadox®

​

​

7,972

​

​

22,378

Ximino®

​

​

4,957

​

​

8,247

Zilxi®

​

​

2,273

​

​

—

Exelderm®

​

​

3,463

​

​

5,363

Other branded revenue

​

​

—

​

​

37

Collaboration revenue

​

​

1,882

​

​

5,389

Revenue – related party

​

 

192

​

 

268

Other revenue1

​

​

2,674

​

 

—

Net revenue

​

$

75,743

​

$

68,791

​

Note 1:

Other revenue for the year ended December 31, 2022 included a net $2.5 million milestone payment from Maruho Co., Ltd, upon receipt of marketing and manufacturing approval for Rapifort® Wipes 2.5% (Qbrexza®), as well as $0.2 million in royalties from Maruho on sales of Rapifort® Wipes 2.5% in Japan.